Akari Therapeutics - Aktx-101 Demonstrates Robust Anti-Tumor Activity In Urothelial Cancer Preclinical Models

Akari Therapeutics PLC AKTX.O:

• Akari Therapeutics - AKTX-101 demonstrates robust anti-tumor activity in urothelial cancer preclinical models
• Akari Therapeutics - Ph1 payload shows potential to overcome payload-specific resistance
• Akari Therapeutics - Continues to advance IND-enabling activities for AKTX-101 with goal of initiating Phase 1 clinical trial in mid-2027
• Akari Therapeutics - AKTX-101 achieves statistically significant tumor growth inhibition in urothelial carcinoma model
• Akari Therapeutics - Developing AKTX-102 ADC targeting CEACAM5 in multiple solid tumors